Alliance Pharma PLC Block Listing Six Monthly Return (8182Q)

TIDMAPH

RNS Number : 8182Q

Alliance Pharma PLC

30 June 2022

 
 For immediate release   30 June 2022 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

 
 Name of applicant:                                     ALLIANCE PHARMA PLC 
 Names of schemes:                                      a) The Alliance Pharma plc Approved Share Option Plan 2005 
                                                         b) The Alliance Pharma plc Share Option Plan 2006 
                                                         c) The Alliance Pharma plc Company Share Option Plan 2015 
                                                         d) The Alliance Pharma plc Long-Term Incentive Plan 2019 
                                                       --------------------------------------------------------------- 
 Period of return:              From:                   28 December 2021                To:      28 June 2022 
                               ----------------------  ------------------------------  -------  ---------------------- 
 Number of securities originally admitted at date of    25,000,000 ordinary shares of 1p each 
 admission:                                              28 June 2017 
                                                       --------------------------------------------------------------- 
 Balance of unallotted securities under schemes from    a) 18,618 
 previous return:                                        b) 3,091,781 
                                                         c) 10,399,643 
                                                         d) Nil 
                                                       --------------------------------------------------------------- 
 Plus: The amount by which the block schemes have       a) 167,351 
 been increased since the date of the last               b) Nil 
 return (if any increase has been applied for):          c) Nil 
                                                         d) 1,500,000 
                                                       --------------------------------------------------------------- 
 Less: Number of securities issued/allotted under       a) 24,023 
 schemes during period:                                  b) 540,613 
                                                         c) 745,623 
                                                         d) Nil 
                                                       --------------------------------------------------------------- 
 Equals: Balance under schemes not yet                  e) 161,946 
 issued/allotted at end of period:                       f) 2,551,168 
                                                         g) 9,654,020 
                                                         h) 1,500,000 
                                                       --------------------------------------------------------------- 
 
 
 
 Name of contact:               Chris Chrysanthou, Company Secretary 
 Telephone number of contact:   Tel. [phone] 
                               ------------------------------------- 
 

For further information:

 
 Alliance Pharma plc                              + 44 (0)1249 466966 
 Cora McCallum, Head of Investor Relations 
  & Corporate Communications                      + 44 (0)1249 705168 
 [e-mail] 
 
                                                      + 44 (0)20 7466 
 Buchanan                                                        5000 
 Mark Court / Sophie Wills / Hannah Ratcliff 
 [e-mail] 
 
                                                      + 44 (0)20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Freddie Barnfield / Duncan 
  Monteith 
 Corporate Broking: James Black 
 
                                                      + 44 (0)20 7597 
 Investec Bank plc                                               5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRURAKRUAUNORR

(END) Dow Jones Newswires

June 30, 2022 05:14 ET (09:14 GMT)